• Home Study Details

  • Home / Learn / Home Study CE / Home Study Details


An Impartial Approach to Partial Agonism: A Buprenorphine Review

Program Type

OnDemand

Credits

1.25 Contact Hour(s)

Release Date

Monday, March 14, 2022

Offline Date:

Thursday, March 14, 2024

ACPE Expiration Date

Thursday, March 14, 2024

Target Audience

Pharmacist, Pharmacy Technician

Cost

$4.00

  • Overview

    Buprenorphine is perhaps the most highly misunderstood medication of our time, or at least within the pain management pharmacological treatment options. Being utilized within the indications of pain management and opioid use disorder (opioid addiction) certainly propels it to the top of any polarized discussions to say the least. So how does one navigate through the pharma-sea of opinions? Join us for a dynamic discussion on the complicated simplicities of buprenorphine pharmacology including partial mu opioid agonism, mu opioid receptor affinity, half-life related dosage selections, CYP-450 metabolism and respective interactions, maximum dosage recommendations, morphine milligram equivalent (MME) calculations, and the infamous respiratory depression relative ceiling effects. Dispelling every rumor, one pharmacological principal at a time, helping you help your patients every day.

    Handouts

    Slide Document:   21227H08_2pp.pdf
    Slide Document:   21227H08_6pp.pdf

    Financial Support By

    PharmCon
  • Pharmacist

    Differentiate buprenorphine prescription products by FDA approved indications for pain management and opioid use disorder.
    Describe buprenorphine’s atypical prescription opioid mechanism of action as a partial mu opioid agonist with greater than average mu opioid receptor affinity and relative respiratory depression ceiling effect.
    Recall buprenorphine’s pharmacological properties relevant to patient care including CYP-3A4 interactions, long half-life, maximum recommended dosage, and morphine milligram equivalency.


    Pharmacy Technician

    Differentiate buprenorphine prescription products by FDA approved indications for pain management and opioid use disorder.
    Describe buprenorphine’s atypical prescription opioid mechanism of action as a partial mu opioid agonist with greater than average mu opioid receptor affinity and relative respiratory depression ceiling effect.
    Recall buprenorphine’s pharmacological properties relevant to patient care including CYP-3A4 interactions, long half-life, maximum recommended dosage, and morphine milligram equivalency.

  • Activity Type

    Knowledge

    Universal Activity Number

    Pharmacist 0798-0000-21-227-H08-P

    Pharmacy Technician 0798-0000-21-227-H08-T

    ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

    In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


HARDWARE REQUIREMENTS
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
 


SOFTWARE REQUIREMENTS
Microsoft Edge
Internet Explorer 8.0 or higher
Google Chrome
Safari
Firefox 3.0.3 or higher


NETWORK REQUIREMENTS
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
 
 

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

 

©2015 PharmCon All Rights Reserved | Terms & Conditions | Privacy PolicyContinuing Education For Healthcare Professionals
Developed By: ITB, Inc.